A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDC’s advisory committee has come under scrutiny for referencing a non-existent study. The report, “Thimerosal as a Vaccine Preservative,” authored by Lyn Redwood—former leader of the anti-vaccine group Children’s Health Defense—cited a 2008 study allegedly co-authored by UC Davis Professor Emeritus Robert Berman. However, Berman confirmed that such a study was never conducted by him and said the cited findings misrepresented his actual research published in Toxicological Sciences.
The erroneous citation was first reported by Reuters, prompting the CDC to upload a revised version of Redwood’s presentation, removing the disputed slide. The controversy has intensified after Health Secretary Robert F. Kennedy Jr. recently replaced the CDC’s entire 17-member vaccine panel with eight new members, half of whom are known vaccine skeptics.
Both Republican Senator Bill Cassidy and Democratic Senator Patty Murray have urged postponement of the June 25–26 meeting, citing the panel’s lack of vetting and the absence of a CDC director. Redwood’s presentation contrasts with a separate CDC staff report reaffirming that thimerosal-containing vaccines do not cause autism or other neurodevelopmental issues.
According to CDC data, 96% of flu vaccines administered during the 2024–25 season were thimerosal-free, and only 0.3% of flu vaccines given to pregnant women contained the preservative. Kennedy, a long-time critic of vaccine safety, has previously claimed thimerosal causes brain damage—claims consistently debunked by scientific research.
The thimerosal debate highlights rising tensions around vaccine policy and misinformation, especially as newly appointed CDC advisors consider whether to recommend thimerosal-free vaccines for all pregnant women and children. Redwood has not yet responded to requests for comment.


Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Australia Day Protests Highlight Deep Divisions Over Indigenous Rights and Immigration
Trump Administration Gun Comments Spark Rift With NRA Ahead of Midterms
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Neuralink Expands Brain Implant Trials with 12 Global Patients
Trump Claims Breakthrough in Syria Talks After Call With President al-Sharaa
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
U.S. Links Security Guarantees to Ukraine Peace Deal Talks With Russia
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Kim Jong Un Signals Expanded Nuclear Plans Ahead of Workers’ Party Congress
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



